GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Operating Income

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Operating Income : HK$-209 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Operating Income?

Sihuan Pharmaceutical Holdings Group's Operating Income for the six months ended in Dec. 2023 was HK$-258 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-209 Mil.

Warning Sign:

Sihuan Pharmaceutical Holdings Group Ltd had lost money in 67% of the time over the past 3quarters.

Operating Margin % is calculated as Operating Income divided by its Revenue. Sihuan Pharmaceutical Holdings Group's Operating Income for the six months ended in Dec. 2023 was HK$-258 Mil. Sihuan Pharmaceutical Holdings Group's Revenue for the six months ended in Dec. 2023 was HK$880 Mil. Therefore, Sihuan Pharmaceutical Holdings Group's Operating Margin % for the quarter that ended in Dec. 2023 was -29.26%.

Sihuan Pharmaceutical Holdings Group's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sihuan Pharmaceutical Holdings Group's annualized ROC % for the quarter that ended in Dec. 2023 was -7.17%. Sihuan Pharmaceutical Holdings Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.53%.


Sihuan Pharmaceutical Holdings Group Operating Income Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Operating Income Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,503.16 532.10 793.06 -618.89 -209.44

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -112.88 63.15 -679.05 48.12 -257.57

Sihuan Pharmaceutical Holdings Group Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-209 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sihuan Pharmaceutical Holdings Group  (HKSE:00460) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sihuan Pharmaceutical Holdings Group's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-515.13 * ( 1 - -8.22% )/( (6768.531 + 8778.334)/ 2 )
=-557.473686/7773.4325
=-7.17 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12879.079 - 1586.963 - ( 4932.938 - max(0, 2453.247 - 6976.832+4932.938))
=6768.531

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12617.21 - 1545.273 - ( 4900.608 - max(0, 4491.933 - 6785.536+4900.608))
=8778.334

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Sihuan Pharmaceutical Holdings Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=16.602/( ( (3187.787 + max(-854.295, 0)) + (3108.551 + max(-3053.197, 0)) )/ 2 )
=16.602/( ( 3187.787 + 3108.551 )/ 2 )
=16.602/3148.169
=0.53 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(463.49 + 672.998 + 179.433) - (1586.963 + 0 + 583.253)
=-854.295

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(369.217 + 609.588 + 132.189) - (1545.273 + 0 + 2618.918)
=-3053.197

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Sihuan Pharmaceutical Holdings Group's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-257.565/880.31
=-29.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Sihuan Pharmaceutical Holdings Group Operating Income Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.
Executives
Che Fengsheng 2201 Interest of corporation controlled by you
Guo Weicheng 2201 Interest of corporation controlled by you
Meng Xianhui 2201 Interest of corporation controlled by you
Zhang Jionglong 2201 Interest of corporation controlled by you
Mingyao Capital Limited 2401 A concert party to an agreement to buy shares
Network Victory Limited 2401 A concert party to an agreement to buy shares
Proper Process International Limited 2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited 2101 Beneficial owner
Victory Faith International Limited 2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd 2301 Trustee
Ubs Trustees (cayman) Ltd. 2301 Trustee
Smart Top Overseas Limited 2501 Other
Plenty Gold Enterprises Limited 2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines